Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 6/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine 3-Glucuronide SCHEMBL3843209 | 1.00 | MRGPRX2 (0.74) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL3017103 | 0.92 | MRGPRX2 (0.89) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL2171816 | 0.92 | MRGPRX2 (0.89) | MRGPRX2OPRM1OPRD1OPRK1 | |
| SCHEMBL1032567 | 0.89 | OPRD1 (0.71) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| Morphine 3-Glucuronide SCHEMBL8409700 | 0.86 | OPRM1 (0.62) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| Morphine 3-Glucuronide SCHEMBL8412630 | 0.86 | OPRM1 (0.62) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL6753388 | 0.85 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL8409352 | 0.85 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| SCHEMBL1261490 | 0.85 | MRGPRX2 (1.00) | MRGPRX2OPRM1OPRD1OPRK1ADRB1 | |
| Morphine SCHEMBL9219855 | 0.84 | OPRM1 (0.75) | MRGPRX2OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884029-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2018-02-06 | — | — | US | claimed |
| US-20170267985-A1 | MUTANT LACTOBACILLUS BETA-GLUCURONIDASE ENZYMES WITH ENHANCED ENZYMATIC ACTIVITY | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. | 2017-09-21 | — | — | US | claimed |
| US-20160361269-A1 | MORPHINE CONTROLLED RELEASE SYSTEM | EGALET LTD. (GB) | 2016-12-15 | — | — | US | claimed |
| US-20160237415-A1 | MUTANT STAPHYLOCOCCUS BETA-GLUCURONIDASE ENZYMES WITH ENHANCED ENZYMATIC ACTIVITY | INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. | 2016-08-18 | — | — | US | claimed |
| US-9375428-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2016-06-28 | — | — | US | claimed |
| EP-2301526-B1 | Morphine controlled release system | EGALET LTD (GB) | 2016-03-23 | — | — | EP | claimed |
| US-20150079150-A1 | MORPHINE CONTROLLED RELEASE SYSTEM | EGALET LTD. (GB) | 2015-03-19 | — | — | US | claimed |
| EP-2844733-A1 | IN VITRO MODEL FOR PATHOLOGICAL OR PHYSIOLOGIC CONDITIONS | Hemoshear, LLC (US) | 2015-03-11 | — | — | EP | claimed |
| CN-104350142-A | In vitro model for pathological or physiologic conditions | HEMOSHEAR LLC | 2015-02-11 | — | — | CN | claimed |
| US-8877241-B2 | Morphine controlled release system | EGALET LTD. (GB) | 2014-11-04 | — | — | US | claimed |
| US-20030130314-A1 | Analgesic delivery systems and methods of use | ARYX THERAPEUTICS | 2003-07-10 | — | — | US | claimed |
| WO-2003051363-A1 | ANALGESIC DELIVERY SYSTEMS AND METHODS OF USE | ARYX THERAPEUTICS (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2003024430-A1 | MORPHINE POLYMER RELEASE SYSTEM | EGALET A/S (DK) | 2003-03-27 | — | — | WO | claimed |
| US-5908927-A | Synthesis of deuterated opiate glucuronides | HIGH STANDARD PRODUCTS CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| EP-0471740-B1 | ENZYMES AND THEIR USE IN DRUG DETECTION | BRITISH TECH GROUP (GB) | 1995-08-09 | — | — | EP | claimed |
| US-5387515-A | Oxidation in the presence of the enzyme and cofactor nadp | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-02-07 | — | — | US | claimed |
| US-5298414-A | Polypeptides, oxidation for detection | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-03-29 | — | — | US | claimed |
| EP-0471740-A1 | ENZYMES AND THEIR USE IN DRUG DETECTION. | NAT RES DEV (GB) | 1992-02-26 | — | — | EP | claimed |
| WO-1990013634-A2 | ENZYMES AND THEIR USE IN DRUG DETECTION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1990-11-15 | — | — | WO | claimed |
| US-4939264-A | Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies | ABBOTT LABORATORIES (US) | 1990-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130314-A1 | Analgesic delivery systems and methods of use | OPRL1, OPRK1, OPRM1 | MRGPRX2 217/4885OPRM1 3/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.